These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8219918)

  • 1. von Willebrand factor and the endothelium in vascular disease.
    Blann A
    Br J Biomed Sci; 1993 Jun; 50(2):125-34. PubMed ID: 8219918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand factor in diabetic angiopathy.
    Kessler L; Wiesel ML; Attali P; Mossard JM; Cazenave JP; Pinget M
    Diabetes Metab; 1998 Sep; 24(4):327-36. PubMed ID: 9805643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand factor propeptide in vascular disorders.
    van Mourik JA; Romani de Wit T
    Thromb Haemost; 2001 Jul; 86(1):164-71. PubMed ID: 11487004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand factor, endothelial dysfunction, and cardiovascular disease.
    Vischer UM
    J Thromb Haemost; 2006 Jun; 4(6):1186-93. PubMed ID: 16706957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes.
    Spiel AO; Gilbert JC; Jilma B
    Circulation; 2008 Mar; 117(11):1449-59. PubMed ID: 18347221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the von Willebrand factor with platelets and thrombosis.
    Perutelli P; Mori PG
    Recenti Prog Med; 1997 Nov; 88(11):526-9. PubMed ID: 9401429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation.
    Ruggeri ZM
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):257-79. PubMed ID: 11686099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor.
    Makin AJ; Blann AD; Chung NA; Silverman SH; Lip GY
    Eur Heart J; 2004 Mar; 25(5):371-6. PubMed ID: 15033248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Von Willebrand factor in coronary disease].
    Soskin P; Wiesel ML; Mossard JM; Arbogast R; Najib K; Grunebaum L; Sacrez A; Cazenave JP
    Arch Mal Coeur Vaiss; 1994 Jan; 87(1):85-93. PubMed ID: 7811156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
    Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY
    J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endothelium and hemorrhages].
    Mazurier C; Goudemand J
    Rev Prat; 1997 Dec; 47(20):2233-8. PubMed ID: 9616911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
    Hoylaerts MF
    Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors.
    Hlubocká Z; Umnerová V; Heller S; Peleska J; Jindra A; Jáchymová M; Kvasnicka J; Horký K; Aschermann M
    J Hum Hypertens; 2002 Aug; 16(8):557-62. PubMed ID: 12149661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate.
    Blann AD
    Z Rheumatol; 1991; 50(5):320-2. PubMed ID: 1723232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report.
    Lip GY; Blann AD; Zarifis J; Beevers M; Lip PL; Beevers DG
    J Hypertens; 1995 Dec; 13(12 Pt 2):1674-8. PubMed ID: 8903631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial cell activation in cutaneous vasculitis.
    Jurd KM; Stephens CJ; Black MM; Hunt BJ
    Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetics of von Willebrand disease.
    Mazurier C; Ribba AS; Gaucher C; Meyer D
    Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The presence of active von Willebrand factor under various pathological conditions.
    Groot E; de Groot PG; Fijnheer R; Lenting PJ
    Curr Opin Hematol; 2007 May; 14(3):284-9. PubMed ID: 17414220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VWF attributes--impact on thrombus formation.
    Reininger AJ
    Thromb Res; 2008; 122 Suppl 4():S9-13. PubMed ID: 18929523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation and destruction of primary thrombi under the influence of blood flow and von Willebrand factor analyzed by a discrete element method.
    Miyazaki H; Yamaguchi T
    Biorheology; 2003; 40(1-3):265-72. PubMed ID: 12454415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.